Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...